Premium Beauty Stocks With Real Profits After The Victoria Beckham Beauty Buzz

Victoria Beckham Holdings just turned an operating profit of £7.3m in 2025 after years of red ink, and its beauty arm is attracting waitlists of 25,000 people for a single product. That kind of demand can focus attention on profitable premium beauty and skincare stocks that might also benefit from similar brand power. This article walks through three such stocks exposed to the same news story and explains why they may deserve a closer look at this time.

The stocks covered below are just a starting sample, and the full screen on Simply Wall St has surfaced 16 more profitable premium beauty and skincare companies with similarly interesting stories that are not included here. To identify and analyze the highest conviction ideas from that wider group, head straight into the Profitable Premium Beauty and Skincare Brands screener.

Gr. Sarantis (ATSE:SAR)

Gr. Sarantis is a €0.9b Athens based producer and trader of branded cosmetics and household products that gives you direct exposure to beauty and skincare margins rather than general retail. It generates about €205 million from Home Care Solutions, €112 million from Personal Care and €73 million from Beauty, Skin and Sun Care, with additional revenue from private label and distribution partnerships across Europe and beyond. This blend of premium beauty exposure and scale across multiple product lines underpins its place in the Profitable Premium Beauty and Skincare Brands screener.

Gr. Sarantis may appeal if you want a profitable route into premium beauty where brand power and margin mix are important. Management has been increasing focus on higher margin Beauty, Skin and Sun Care and export channels, while maintaining EBITDA and EBIT margins at levels that fit the screener’s focus on quality earnings. At the same time, an unstable dividend record, reliance on external borrowing and a relatively new board mean you need to be comfortable with some balance sheet and governance risk. For investors willing to weigh those trade offs, there is more to explore in how this €0.9b company is using its European footprint to address premium beauty demand and respond to the kind of buzz seen in recent viral launches.

Gr. Sarantis is quietly shifting toward higher margin beauty and skincare, yet the real story sits in how earnings quality and balance sheet pressure intersect. Get the full picture in the 3 key rewards and 1 important warning sign

Matas (CPSE:MATAS)

Matas runs a large Nordic beauty and wellbeing retail platform that fits the screener’s focus on profitable premium beauty and skincare, with strong exposure to prestige brands and hero product launches across its stores and online channels. The core Matas banner generates about DKK 4.97b in revenue, with the Kicks chain adding DKK 3.26b and other activities contributing DKK 633 million, providing broad exposure to beauty, personal care and adjacent categories. The company carries a market cap of about DKK 3.3b.

Matas provides access to premium beauty demand across Denmark and the wider Nordic region at scale, from high-end brands in Kicks to owned labels and an app-led loyalty base. Management is working to lift margins and earnings through a unified digital platform, exclusive brands and logistics efficiencies, while also running a sizable buyback program that reduces the free float. Risks include recent margin pressure, high reliance on debt funding and a competitive Nordic beauty market that could limit the benefit from hero product launches. For investors evaluating the balance between premium exposure, earnings quality and balance sheet risk, Matas may warrant a closer look.

Matas is working to combine Nordic scale, premium brands and a powerful loyalty base, yet the real story may be how its debt and margin pressure shape that potential. Get the full context in the analysis report for Matas

PZ Cussons (LSE:PZC)

PZ Cussons owns a portfolio of baby, beauty and hygiene brands such as St. Tropez, Sanctuary Spa and Cussons Baby that fits the screener’s focus on profitable premium beauty and skincare products with potential hero lines. It generates about £202 million of revenue from Europe and the Americas, £176 million from Asia Pacific and £168 million from Africa, with a smaller £46 million Central segment and eliminations of £52 million, and has a market cap of roughly £436 million.

Investors looking at premium beauty may wish to pay attention to PZ Cussons because it combines direct exposure to brands like St. Tropez with a recent swing back to profit and a growing dividend, while management is simplifying the portfolio and focusing on higher margin products. The flip side is meaningful exposure to Nigeria’s currency and inflation, a history of earnings volatility and reliance on external borrowing, so the recovery story still needs proof that improved margins and a premium product mix can hold through tougher markets.

PZ Cussons’ renewed profit and premium brands story can look stronger than it first appears, yet the real test sits in the details of its cash generation and Nigeria risk mix in the PZ Cussons financial health report

Seeking Alternatives Before The Crowd

Fresh ideas move first. Stocks can gain momentum, lose steam or get caught flying under the radar for now. Use these focused screens before the window drops and consider your options promptly.

• Identify early breakouts in smaller companies before momentum headlines arrive by scanning the 211 elite penny stocks with strong financials while it still flies under most radars.
• Follow structural shifts in digital money by tracking the 19 cryptocurrency and blockchain stocks and see which businesses are building real projects while interest swings widely.
• Monitor major infrastructure themes by checking the 39 power grid technology and infrastructure stocks and see which companies may benefit if grid upgrades increase.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com